NorthCrest Asset Manangement LLC bought a new stake in  Zoetis Inc. (NYSE:ZTS – Get Rating) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,450 shares of the company’s stock, valued at approximately $213,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its position in  Zoetis by 430.8% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after buying an additional 112 shares in the last quarter.  Worth Asset Management LLC acquired a new position in  Zoetis during the first quarter valued at approximately $26,000.  Psagot Value Holdings Ltd. Israel acquired a new position in  Zoetis during the third quarter valued at approximately $25,000.  EWG Elevate Inc. acquired a new position in  Zoetis during the fourth quarter valued at approximately $27,000.  Finally, McClarren Financial Advisors Inc. acquired a new position in  Zoetis during the third quarter valued at approximately $31,000. 90.23% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE:ZTS opened at $174.45 on Wednesday. The company has a current ratio of 2.37, a quick ratio of 1.63 and a debt-to-equity ratio of 1.49. The company has a fifty day simple moving average of $167.42 and a 200 day simple moving average of $157.12. The firm has a market cap of $80.69 billion, a PE ratio of 38.77, a price-to-earnings-growth ratio of 2.70 and a beta of 0.77. Zoetis Inc. has a 12-month low of $124.15 and a 12-month high of $190.80.

Zoetis (NYSE:ZTS – Get Rating) last released its earnings results on Tuesday, February 14th. The company reported $1.15 earnings per share for the quarter, meeting the consensus estimate of $1.15. Zoetis had a net margin of 26.16% and a return on equity of 50.20%. The firm had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.01 billion. During the same quarter in the previous year, the firm earned $1.00 earnings per share. The firm’s revenue for the quarter was up 3.7% compared to the same quarter last year.  On average, equities research analysts anticipate that  Zoetis Inc. will post 5.39 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 1st. Shareholders of record on Friday, April 21st will be paid a dividend of $0.375 per share. The ex-dividend date of this dividend is Thursday, April 20th. This represents a $1.50 annualized dividend and a yield of 0.86%. Zoetis’s payout ratio is 33.33%.

ZTS has been the topic of a number of recent research reports. StockNews.com initiated coverage on shares of Zoetis in a research report on Thursday, March 16th. They set a “buy” rating on the stock. Bank Of America (Bofa) boosted their target price on shares of Zoetis from $180.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, April 11th. Finally, Barclays boosted their target price on shares of Zoetis from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 21st. Nine investment analysts have rated the stock with a buy rating,  According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $220.43.

Zoetis, Inc engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The United States segment is involved in U. S.

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.